Large gap with delayed quotes
|
Last quote
04/27/2026
-
16:33:47
|
Bid
04/27/2026 -
16:35:15
|
Bid Volume |
Ask
04/27/2026 -
16:35:15
|
Ask Volume |
|---|---|---|---|---|
|
32.87
+0.12
(
+0.37% )
|
32.84
|
100 |
32.91
|
100 |
Analysis date: 24.04.2026
Global Evaluation
Negativ
Negativ
The stock is classified in the negative zone since 14.04.2026.
Interest
Very weak
Very weak
One star since 14.04.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 14.04.2026 at a price of 35.52.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded above its moving average since 03.04.2026.
4wk Rel Perf
-7.48%
-7.48%
The four-week dividend-adjusted underperformance versus SP500 is 7.48%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 0.97%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.57%.
Mkt Cap in $bn
3.80
3.80
With a market capitalization between $2 & $8bn, VIKING THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
-1
-1
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
-7.82
-7.82
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
-7.82%
-7.82%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
16
16
Over the last seven weeks, an average of 16 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
134
134
For 1% of index variation, the stock varies on average by 1.34%.
Correlation
0.25
0.25
Stock movements are strongly independent of index variations.
Value at Risk
18.66
18.66
The value at risk is estimated at USD 18.66. The risk is therefore 56.98%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
22.11.2024
22.11.2024